CYBIN INC. (HELP) Form 6-K — Aug 14, 2026
Cybin Inc., doing business as Helus Pharma (Nasdaq: HELP), filed its 6-K with unaudited financial statements for the three months ended June 30, 2026. The company reported a net loss of $47.8 million, nearly double the $24.6 million loss in the prior-year quarter, with a basic and diluted loss per share of $0.91 versus $1.10 a year ago. Cash stood at $166.4 million at June 30, 2026, bolstered by a June 25, 2026 underwritten offering of 10,309,280 common shares at $4.85 per share for gross proceeds of $50 million, led by Cantor Fitzgerald, Barclays Capital, Bloom Burton Securities and Lucid Capital Markets.
Key figures
- Cash Position
- 166365000
- Gross Proceeds
- 50000000
- Offering Price
- 4.85
- Shares Offered
- 10309280
- Shares Outstanding
- 61984078
- Research Expenses
- 30761000
- Operating Expenses
- 49082000
- Weighted Avg Shares
- 52318151
- Warrants Outstanding
- 12205335
- General Admin Expenses
- 6747000
- Lockup Released Shares
- 1916362
- Net Cash Used In Operating
- 37070000
- Share Based Compensation
- 11574000
- Underwriter Cash Commission
- 3000000
- Prior Year Weighted Avg Shares
- 22401197
- Aug10 Warrant Exercise Proceeds
- 1538000
- Subsequent Accelerated Sbc Expense
- 15425000
- Warrant Weighted Avg Exercise Price
- 10.11
- Subsequent Shares Issued On Rsu Vesting
- 7889846
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.